Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Colombo, Federico ^a   Trombetta, Elena ^a   Cetrangolo, Paola ^a   Maggioni, Marco ^a   Razini, Paola ^b   De Santis, Francesca ^b   Torrente, Yvan ^b   Prati, Daniele ^c   Torresani, Erminio ^a   Porretti, Laura ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BETA1 INTEGRIN; BREAST CANCER RESISTANCE PROTEIN; CD56 ANTIGEN; HERMES ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PEROXISOMAL MEMBRANE PROTEIN 70; PROTEIN DISULFIDE ISOMERASE; SORAFENIB; SUNITINIB; THY 1 ANTIGEN; UNCLASSIFIED DRUG; VACUOLE MEMBRANE PROTEIN 1; VERAPAMIL; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CARCINOMA CELL LINE; CELL MEMBRANE; CELL VACUOLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; GIANT LYSOSOME; HCC 1 CELL LINE; HEP3B CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; INCUBATION TIME; LYSOSOME; MOLECULAR DYNAMICS; MTT ASSAY; MULTIDRUG RESISTANCE; PLC CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SMALL LYSOSOME; SNU475 CELL LINE; TIME LAPSE IMAGING; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; LIVER NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDOLES; LIVER NEOPLASMS; LYSOSOMES; PYRROLES;

EID: 84918507737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114787     Document Type: Article

References (28)

1. Fodale V, Pierobon M, Liotta L, Petricoin E (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17: 89-95.
2. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
3. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166.
4. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA (2003) Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22: 7458-7467.
5. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
6. Falasca M, Linton KJ (2012) Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 21: 657-666.
7. Zhu H, Luo SF, Wang J, Li X, Wang H, et al. (2012) Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxia-inducible factor-1a. Chin Med J 125: 1095-1103.
8. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE (1991) Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77: 348-354.
9. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, et al. (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78: 153-161.
10. Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279: 149-157.
11. Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, et al. (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641-647.
12. Bates S, Kang M, Meadows B, Bakke S, Choyke P, et al. (2001) A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92: 1577-1590.
13. Wang XB, Wang SS, Zhang QF, Liu M, Li HL, et al. (2010) Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep 23: 211-215.
14. Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18: 350-356.
15. Ughachukwu P, Unekwe P (2012) Efflux pump-mediated resistance in chemotherapy. Ann Med Health Sci Res 2: 191-198.
16. Ifergan I, Scheffer GL, Assaraf YG (2005) Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res 65: 10952-10958.
17. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, et al. (2011) Lysosomal sequestration of Sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17: 7337-7346.
18. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, et al. (2013) P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 288: 31761-31771.
19. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, et al. (2011) Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One 6: e21369.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
21. Meaney M, Savage J, Brennan GP, Hoey E, Trudgett A, et al. (2013) Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil. Parasitology 140: 1287-1303.
22. Blott EJ, Griffiths GM (2002) Secretory lysosomes. Nat Rev Mol Cell Biol 3: 122-131.
23. Date S, Mizuno H, Tsuyama N, Harada T, Masujima T (2012) Direct drug metabolism monitoring in a live single hepatic cell by video mass spectrometry. Anal Sci 28: 201-203.
24. Goldman SD, Funk RS, Rajewski RA, Krise JP (2009) Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis 1: 1445-1459.
25. Sun Z, Zhao Z, Li G, Dong S, Huang Z, et al. (2010) Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: In vivo and clinical studies. Tumori 96: 90-96.
26. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47: 545-552.
27. Pingsheng F, Tengyue Z, Qiang H, Qiang W, Xin S, et al. (2012) Basic and clinical research on the therapeutic effect of intervention in primary liver cancer by targeted intra-arterial verapamil infusion. Cell Biochem Biophys 62: 59-67.
28. Huang J, Duan Q, Fan P, Ji C, Lv Y, et al. (2011) Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma. Cell Biochem Biophys 59: 127-132.